New FDA Center Aims to Expedite Cancer Treatment Reviews

The Oncology Center of Excellence, a product of the White House’s Cancer Moonshot initiative, will bring together oncologists across the US Food and Drug Administration.

Jun 30, 2016
Alison F. Takemura

NATIONAL CANCER INSTITUTE, RHODA BAER Applications to approve cancer treatments are currently evaluated at three different centers within the US Food and Drug Administration (FDA), which address drugs, biologics, and devices separately. As part of the White House’s $1 billion Cancer Moonshot initiative, the FDA has created a new organizing body: the Oncology Center of Excellence (OCE). The FDA named oncologist Richard Pazdur, current director of the agency’s Center for Drug Evaluation and Research, acting director of the OCE, Reuters reported yesterday (June 29).

“The OCE will expedite the development of novel combination products and support an integrated approach to tackle this devastating disease that touches so many American families,” the FDA said in a statement.